免疫检查点抑制剂和代谢事件:来自欧洲安全分析的结果

相关实验视频

Updated: Jan 15, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Miriam Longo^1,2, Annamaria Mascolo^3,4, Gabriella di Mauro^5,6

¹Department of Advanced Medical and Surgical Sciences, Division of Endocrinology and Diabetes, University of Campania "Luigi Vanvitelli", P.zza L. Miraglia, 2, Naples, 80138, Italy.

Hormones (Athens, Greece)

|October 15, 2025

概括

免疫检查点抑制剂 (ICI),特别是抗编程死亡-1 (PD1) 疗法,与1型和2型糖尿病报告的增加有关. 需要进一步的研究来了解这种关联背后的机制.

科学领域:

内分泌学在内分泌学.
药物监督药物监督药物监督
在瘤学瘤学.

背景情况:

免疫检查点抑制剂 (ICI) 包括编程死亡-1 (PD1),编程死亡联结1 (PDL1) 和细胞毒性T淋巴细胞相关抗原4 (CTLA-4) 抑制剂.
ICI与内分泌免疫相关的不良事件有关.
本研究分析了欧洲药监数据库中与ICI报告的代谢不良事件.

研究的目的:

描述与ICI相关的代谢事件的个体病例安全报告 (ICSR).
为了比较不同类型的ICI之间的代谢影响报告频率.

主要方法:

追溯的欧洲药监测研究.
对2018年至2022年与ICI相关的代谢事件的ICSR分析.
对抗PD1,抗PDL1和抗CTLA-4疗法的代谢事件报告率的比较.

主要成果:

确定了6220个涉及ICI和代谢事件的ICSR;布罗利祖马布和尼沃卢马布是最常见的.
1型糖尿病和糖尿病酸性糖尿病是最常见的血糖变化.
与抗PDL1和抗CTLA-4疗法相比,抗PDL1疗法对1型糖尿病和2型糖尿病的报告频率更高.
老年人 (≥65岁) 报告1型糖尿病的概率明显更高.

结论:

抗PD1疗法与1型和2型糖尿病报告的增加有关.
需要进一步的纵向研究来阐明这种关联背后的病原遗传机制.

关键词:

免疫检查点抑制剂免疫检查点抑制剂代谢事件是代谢事件.药物监督药物监督药物监督安全的安全的安全的安全的安全.自发的报告自发报告.

更多相关视频

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

相关概念视频

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...